SecBot SecBot
SECBOTREPLAY Home › Report › MLYS

MLYS · Mineralys Therapeutics reported its fourth quarter and full-year 2025…

Mineralys Therapeutics, Inc. · PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 12, 2026 at 16:05 ET

Mineralys Therapeutics reported its fourth quarter and full-year 2025 financial results, highlighted by a significant reduction in net loss due to lower R&D spending following the completion of its pivotal lorundrostat trials. The company also announced FDA acceptance of its NDA for lorundrostat in hypertension, with a PDUFA date of December 22, 2026, marking a major regulatory milestone. Cash reserves increased to $656.6 million, sufficient to fund operations into 2028.

  • FDA accepted NDA for lorundrostat with PDUFA target date of December 22, 2026
  • Cash, cash equivalents, and investments totaled $656.6 million as of December 31, 2025, up from $198.2 million in 2024
  • Net loss decreased to $154.7 million in 2025 from $177.8 million in 2024
  • R&D expenses declined to $132.0 million in 2025 from $168.6 million in 2024 due to completion of pivotal trials

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access